GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » 3-Year EBITDA Growth Rate

Dianthus Therapeutics (Dianthus Therapeutics) 3-Year EBITDA Growth Rate : 0.00% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics 3-Year EBITDA Growth Rate?

Dianthus Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was $-0.69.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Competitive Comparison of Dianthus Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Dianthus Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dianthus Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Dianthus Therapeutics's 3-Year EBITDA Growth Rate falls into.



Dianthus Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Dianthus Therapeutics  (NAS:DNTH) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Dianthus Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Traded in Other Exchanges
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines